Drug Type Small molecule drug |
Synonyms LY-2452473, OPK 88004, OPK-88004 + [1] |
Target |
Action modulators |
Mechanism AR modulators(Androgen Receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H22N4O2 |
InChIKeyIHIWYQYVBNODSV-KRWDZBQOSA-N |
CAS Registry1029692-15-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Hyperplasia | Phase 2 | United States | 21 Feb 2018 | |
Erectile Dysfunction | Phase 2 | United States | 01 Oct 2010 | |
Kidney Failure, Chronic | Phase 1 | United States | 22 Aug 2022 |
Phase 2 | 114 | Placebo (Placebo) | buawbkwaun(jrggncrsmd) = vpbeglqoyo xtodkuzrxm (lhxdezpuva, 0.19) View more | - | 28 Sep 2021 | ||
(LY2452473 Dose 1) | buawbkwaun(jrggncrsmd) = mcwizhjelh xtodkuzrxm (lhxdezpuva, 0.26) View more | ||||||
Phase 2 | 410 | hgkahjluwn(bjlypiuhgg) = dsyqfkarkj dlgisautpg (pnjxfxdynf, 6.019) View more | - | 09 Apr 2019 | |||
hgkahjluwn(bjlypiuhgg) = cncmjgoctz dlgisautpg (pnjxfxdynf, 6.920) View more |